Literature DB >> 7551234

Structural and immunological characterization of the vaccine adjuvant QS-21.

C R Kensil1, J Y Wu, S Soltysik.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 7551234     DOI： 10.1007/978-1-4615-1823-5_22

Source DB:  PubMed          Journal:  Pharm Biotechnol        ISSN： 1078-0467


× No keyword cloud information.
  20 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 2.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity.

Authors:  Nikolai Petrovsky
Journal:  Vaccine       Date:  2006-04-12       Impact factor: 3.641

3.  Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-07-19       Impact factor: 3.641

4.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

Review 5.  Recent progress in adjuvant discovery for peptide-based subunit vaccines.

Authors:  Fazren Azmi; Abdullah Al Hadi Ahmad Fuaad; Mariusz Skwarczynski; Istvan Toth
Journal:  Hum Vaccin Immunother       Date:  2013-12-03       Impact factor: 3.452

6.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

Review 7.  Carbohydrate-based immune adjuvants.

Authors:  Nikolai Petrovsky; Peter D Cooper
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

Review 8.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

9.  An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.

Authors:  Einar M Sigurdsson; Elin Knudsen; Ayodeji Asuni; Cheryl Fitzer-Attas; Daniel Sage; David Quartermain; Fernando Goni; Blas Frangione; Thomas Wisniewski
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

10.  Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis.

Authors:  Liana Tsenova; Ryhor Harbacheuski; Andre L Moreira; Evette Ellison; Wilfried Dalemans; Mark R Alderson; Barun Mathema; Steven G Reed; Yasir A W Skeiky; Gilla Kaplan
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.